Please provide your email address to receive an email when new articles are posted on . Use of sorefenib led to a modest improvement in progression-free survival for patients with advanced non–small ...

Based on the researchers’ findings, gefapixant provides small benefits in cough severity, cough frequency, and cough-specific quality of life in patients with refractory or unexplained chronic coughs.

Patients with rheumatoid arthritis (RA) treated with leflunomide (Arava) experienced modest but significant weight loss not seen with other RA therapies, a large Veterans Administration study found.

When patients are battling a terminal illness and want access to an experimental drug, how much evidence that it works should regulators require before approval? That’s the question behind many of the ...

Please provide your email address to receive an email when new articles are posted on . Xeljanz rapidly induced remission in patients with moderate-to-severe ulcerative colitis, according to results ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

A recently published study in JAMA Internal Medicine sought to determine whether a symptom and psychosocial collaborative care intervention improves heart failure–specific health status, depression, ...

PARIS, France—For stable coronary artery disease patients caught in physiology-test purgatory—where an assessment of fractional flow reserve (FFR) provides no clear clinical direction—PCI modestly ...

On Friday, the FDA granted accelerated approval to a second Alzheimer’s disease drug in the past two years that trial data show offers modest benefits to patients. With a $26,500 annual price tag and ...

CHICAGO, IL (updated) — More than 9 years since the IMPROVE-IT study was launched, physicians now have their answer when it comes to using ezetimibe (Zetia, Merck/Schering-Plough) in clinical practice ...